1-8 of 8
Bourras-Rezki Bengoudifa
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program

Amer M. Zeidan, Aref Al-Kali, Uma Borate, Thomas Cluzeau, Amy E. DeZern, Jordi Esteve, Aristoteles Giagounidis, Krissy Kobata, Roger Lyons, Uwe Platzbecker, David A. Sallman, Valeria Santini, Guillermo Sanz, Mikkael A. Sekeres, Andrew H. Wei, Zhijian Xiao, Marlies Van Hoef, Claire Nourry-Boulot, Islam Sadek, Bourras-Rezki Bengoudifa, Carolin Sachs, John Sabo, Guillermo Garcia-Manero
Journal: Blood
Blood (2021) 138 (Supplement 1): 4669.
https://doi.org/10.1182/blood-2021-145626
Published: 2021
Journal Articles

Midostaurin in Patients (Pts) with Newly Diagnosed FLT3 -Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial

Jacqueline J Cloos, Pau Montesinos, Walter Fiedler, Rouven Müller, Jürgen Krauter, Simona Sica, Jörg Westermann, Maaike E Heidinga, Lok Lam Ngai, Yvonne J.M Oussoren-Brockhoff, Hartmut Döhner, Mark Levis, Gert J. Ossenkoppele, Richard M. Stone, Giedre Koenen, Bourras-Rezki Bengoudifa, Yuan Cheng, Thierry Medts, Valerie Heidinger, Carolin Sachs, Jorge Sierra
Journal: Blood
Blood (2021) 138 (Supplement 1): 1303.
https://doi.org/10.1182/blood-2021-148129
Published: 2021
Journal Articles

Phase 3b Study Assessing the Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for 7+3 or 5+2 Chemotherapy

Jorge Sierra, MD, Pau Montesinos, MD PhD, Xavier Thomas, MD PhD, Laimonas Griškevičius, MD PhD, Thomas Cluzeau, MD PhD, Denis Caillot, Ollivier Legrand, MD, Clara Minotti, MD, Mario Luppi, Firas Farkas, MD, Bourras-Rezki Bengoudifa, MS, Geralyn Gilotti, MSc, Sejla Hodzic, MD, Alessandro Rambaldi, MD PhD, Adriano Venditti, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–24.
https://doi.org/10.1182/blood-2020-136083
Published: 2020
Journal Articles

Estimand Framework in AML Based on a Randomized, Placebo-Controlled, Phase 3 Study Investigating the Effect of Adding Midostaurin to Standard Chemotherapy in Patients with Newly Diagnosed AML without a FLT3 Mutation

Bourras-Rezki Bengoudifa, Hans Weber, PhD, Insa Gathmann, Albert Hoenekopp, MD, Noah Berkowitz, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5196.
https://doi.org/10.1182/blood-2018-99-119394
Published: 2018
Journal Articles

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

Clinical Trials & Observations
Paul G. Richardson, Vânia T. M. Hungria, Sung-Soo Yoon, Meral Beksac, Meletios Athanasios Dimopoulos, Ashraf Elghandour, Wieslaw W. Jedrzejczak, Andreas Guenther, Thanyaphong Na Nakorn, Noppadol Siritanaratkul, Robert L. Schlossman, Jian Hou, Philippe Moreau, Sagar Lonial, Jae Hoon Lee, Hermann Einsele, Monika Sopala, Bourras-Rezki Bengoudifa, Claudia Corrado, Florence Binlich, Jesús F. San-Miguel
Journal: Blood
Blood (2016) 127 (6): 713–721.
https://doi.org/10.1182/blood-2015-09-665018
Published: 2016
Includes: Supplemental data
Journal Articles

Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment

Jesús F San Miguel, Vânia TM Hungria, Sung-Soo Yoon, Meral Beksac, MD, Meletios A. Dimopoulos, Ashraf Elghandour, MD, Wieslaw W. Jedrzejczak, MD, Andreas Guenther, MD, Thanyaphong Na Nakorn, MD, Noppadol Siritanaratkul, Robert L. Schlossman, MD, Jian Hou, MD PhD, Philippe Moreau, Sagar Lonial, MD, Jae Hoon Lee, Hermann Einsele, MD, Monika Sopala, PhD, Bourras-Rezki Bengoudifa, MS, Claudia Corrado, MD, Florence Binlich, Paul G. Richardson, MD
Journal: Blood
Blood (2015) 126 (23): 4230.
https://doi.org/10.1182/blood.V126.23.4230.4230
Published: 2015
Journal Articles

Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

Jesús F. San-Miguel, MD, Vania T.M. Hungria, MD PhD, Sung-Soo Yoon, MDPhD, Meral Beksac, MD, Meletios A. Dimopoulos, Ashraf Elghandour, MD, Wieslaw W. Jedrzejczak, MD, Andreas Guenther, MD, Thanyaphong Na Nakorn, MD, Noppadol Siritanaratkul, Robert L. Schlossman, MD, Jian Hou, MD PhD, Philippe Moreau, Sagar Lonial, MD, Jae Hoon Lee, MD, Hermann Einsele, MD, Monika Sopala, PhD, Bourras-Rezki Bengoudifa, MS, Claudia Corrado, MD, Paul G. Richardson
Journal: Blood
Blood (2015) 126 (23): 3026.
https://doi.org/10.1182/blood.V126.23.3026.3026
Published: 2015
Journal Articles

A Phase Ib Dose-Finding Study of Oral Panobinostat In Combination with Cytarabine (ara-C) and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia (AML)

Jürgen Krauter, MD, Richard F. Schlenk, MD, Markus Schaich, MD, Didier Bouscary, MD, Hervé Dombret, MD, Ivo J. Winiger, MD, Margaret Squier, MD, PhD, Bourras-Rezki Bengoudifa, Oliver G. Ottmann, MD
Journal: Blood
Blood (2010) 116 (21): 3310.
https://doi.org/10.1182/blood.V116.21.3310.3310
Published: 2010